Here are the key details to know:
1. DEXYCU is the first FDA-approved single dose, sustained release intracameral steroid for the treatment of postoperative inflammation.
2. The code, J1095, will become effective Jan. 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective Oct. 1, 2018.
3. EyePoint Pharmaceuticals still retains transitional pass-through status for DEXYCU from CMS for approximately three years.
More articles on coding, billing and collections:
5 steps ASCs can follow to improve ASC billing performance
Maximize your 2018 reimbursements: Know your health plans, know your market, and stay on top of trends
3 essential elements, benefits to launching a bundled payment program in ASCs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
